Sweden · Delayed Price · Currency is SEK Cell Impact AB Statistics
Total Valuation
Cell Impact AB has a market cap or net worth of SEK 27.67 million. The enterprise value is 41.16 million.
| Market Cap | 27.67M |
| Enterprise Value | 41.16M |
Important Dates
The next confirmed earnings date is Friday, August 21, 2026.
| Earnings Date | Aug 21, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Cell Impact AB has 487.23 million shares outstanding. The number of shares has decreased by -91.90% in one year.
| Current Share Class | 487.23M |
| Shares Outstanding | 487.23M |
| Shares Change (YoY) | -91.90% |
| Shares Change (QoQ) | +38.62% |
| Owned by Insiders (%) | 8.38% |
| Owned by Institutions (%) | 9.02% |
| Float | 446.40M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.23 |
| PB Ratio | 0.27 |
| P/TBV Ratio | 0.29 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 7.78 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.90, with a Debt / Equity ratio of 0.14.
| Current Ratio | 1.90 |
| Quick Ratio | 0.21 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.38 |
| Interest Coverage | -26.32 |
Financial Efficiency
Return on equity (ROE) is -90.35% and return on invested capital (ROIC) is -46.22%.
| Return on Equity (ROE) | -90.35% |
| Return on Assets (ROA) | -41.99% |
| Return on Invested Capital (ROIC) | -46.22% |
| Return on Capital Employed (ROCE) | -113.93% |
| Weighted Average Cost of Capital (WACC) | 18.28% |
| Revenue Per Employee | 211,600 |
| Profits Per Employee | -5.01M |
| Employee Count | 29 |
| Asset Turnover | 0.03 |
| Inventory Turnover | 0.11 |
Taxes
In the past 12 months, Cell Impact AB has paid 36,000 in taxes.
| Income Tax | 36,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -66.19% in the last 52 weeks. The beta is 1.84, so Cell Impact AB's price volatility has been higher than the market average.
| Beta (5Y) | 1.84 |
| 52-Week Price Change | -66.19% |
| 50-Day Moving Average | 0.08 |
| 200-Day Moving Average | 0.18 |
| Relative Strength Index (RSI) | 33.10 |
| Average Volume (20 Days) | 2,929,678 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Cell Impact AB had revenue of SEK 5.29 million and -125.35 million in losses. Loss per share was -4.07.
| Revenue | 5.29M |
| Gross Profit | 212,000 |
| Operating Income | -121.06M |
| Pretax Income | -125.31M |
| Net Income | -125.35M |
| EBITDA | -100.24M |
| EBIT | -121.06M |
| Loss Per Share | -4.07 |
Balance Sheet
The company has 424,000 in cash and 13.91 million in debt, with a net cash position of -13.49 million or -0.03 per share.
| Cash & Cash Equivalents | 424,000 |
| Total Debt | 13.91M |
| Net Cash | -13.49M |
| Net Cash Per Share | -0.03 |
| Equity (Book Value) | 102.14M |
| Book Value Per Share | 0.21 |
| Working Capital | 26.58M |
Cash Flow
In the last 12 months, operating cash flow was -34.80 million and capital expenditures -1.51 million, giving a free cash flow of -36.31 million.
| Operating Cash Flow | -34.80M |
| Capital Expenditures | -1.51M |
| Depreciation & Amortization | 20.82M |
| Net Borrowing | -9.00M |
| Free Cash Flow | -36.31M |
| FCF Per Share | -0.07 |
Margins
| Gross Margin | 4.01% |
| Operating Margin | -2,288.45% |
| Pretax Margin | -2,368.83% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Cell Impact AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 91.90% |
| Shareholder Yield | 91.90% |
| Earnings Yield | -452.94% |
| FCF Yield | -131.20% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on August 25, 2025. It was a reverse split with a ratio of 0.1.
| Last Split Date | Aug 25, 2025 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
Cell Impact AB has an Altman Z-Score of -8.65 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -8.65 |
| Piotroski F-Score | 4 |